The antiviral remdisivir doesn’t reduce viral load or improve patient outcomes. It get a subset of patients (sick, it not too sick and without a bucket full of exclusion criteria) out of the hospital a few days early.

Leronlimab restores immune system, prevents clinical worsening, reverses symptom in three days and, reverses viremia.

And, just a few small points:

Leronlimab has no exclusion criteria.

Leronlimab is a SQ injection

Leronlimab met a designated endpoint without the whole of the FDA rushing to move the goal posts once Gilead had already kicked the ball.

I just realized why the FDA is slow walking Cytodyn. They are still exhausted from moving the goalposts for Gilead remdesevir trial.